Retaspimycin (Hydrochloride)

Retaspimycin (Hydrochloride)

• CAS Number: 857402-63-2
• UNSPSC Description: Retaspimycin Hydrochloride is a potent inhibitor of Hsp90 with EC50s of 119 nM for both Hsp90 and Grp9.
• Target Antigen: HSP
• Type: Reference compound
• Related Pathways: Cell Cycle/DNA Damage;Metabolic Enzyme/Protease
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/Retaspimycin-Hydrochloride.html
• Purity: 96.16
• Solubility: 1M HCl : 100 mg/mL (ultrasonic;adjust pH to 1 with 1M HCl)|DMSO : 100 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic)
• Smiles: O=C(NC1=C2O)/C(C)=C/C=C\[C@H](OC)[C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](CC2=C(C(O)=C1)NCC=C)C)OC)O)C)OC(N)=O.Cl
• Molecular Weight: 624.17
• References & Citations: [1]Patterson J, et al. IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol. 2008 May;61(6):923-32.|[2]Scaltriti M, et al. Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer. Mol Cancer Ther. 2011 May;10(5):817-24.|[3]Sydor JR, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17408-13. Epub 2006 Nov 7.FASEB J. 2023 Mar;37(3):e22832.|Theranostics. 2019 Aug 12;9(20):5769-5783.|Transl Oncol. 2019 Apr 3;12(6):801-809.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, sealed storage, away from moisture)
• Clinical Information: Phase 3